Ipamorelin

Mechanism

Ipamorelin is a growth hormone-releasing peptide that stimulates your pituitary gland to produce more growth hormone in a controlled, pulsatile manner that mimics natural release patterns. Unlike older GH-releasing peptides, it does not significantly increase cortisol or prolactin, making it one of the cleanest options for GH optimization. Users typically report improved sleep quality, better recovery, fat loss, and enhanced skin elasticity.

Effects

## Endocrine/GH Axis [Tier 1 - Human Data] - Pentapeptide growth hormone secretagogue that selectively binds GHS-R1a (ghrelin receptor) on anterior pituitary somatotrophs - Stimulates GH release in a dose-dependent manner: 100mcg produces ~3-5x baseline GH elevation, peaking at 30-40 minutes - UNIQUELY selective among GHRPs: does NOT significantly elevate ACTH, cortisol, prolactin, or aldosterone at therapeutic doses - This selectivity distinguishes it from GHRP-6 (raises cortisol and prolactin, causes intense hunger) and hexarelin (raises cortisol and prolactin, has tachyphylaxis) - Respects somatostatin negative feedback — will NOT cause GH release during a natural somatostatin pulse, preventing supraphysiological GH levels - Synergistic with GHRH analogs (CJC-1295 no DAC, sermorelin): combined use amplifies GH pulse 3-10x vs. either alone ## Metabolic System [Tier 2 - Clinical Observation] - Does NOT significantly increase ghrelin-like hunger (unlike GHRP-6 and MK-677) — patients can inject before bed without hunger disrupting sleep - Supports lipolysis through GH-mediated mechanisms: improved body composition with preferential visceral fat reduction - Fasting insulin and glucose generally stable or improved at standard doses - Modest elevation in free fatty acids post-injection (acute GH-mediated lipolysis) — clinically insignificant ## Musculoskeletal System [Tier 2 - Clinical Observation] - Improved post-exercise recovery through GH/IGF-1 mediated protein synthesis support - Enhanced collagen synthesis benefits tendons, ligaments, and cartilage over months of use - Not anabolic in the traditional sense — does not build muscle like testosterone or nandrolone - Bone density support through IGF-1 mediated osteoblast activity (long-term theoretical benefit) ## Central Nervous System [Tier 2 - Clinical Observation] - Deep sleep enhancement is the most consistently reported benefit by patients - GH release during deep sleep is amplified when ipamorelin is dosed pre-bedtime - Vivid dreams common in first 2-4 weeks, typically normalize - No direct CNS effects — does not cross blood-brain barrier in significant amounts - Mood and cognitive improvements reported are likely secondary to improved sleep quality ## Integumentary System [Tier 2 - Clinical Observation] - Improved skin thickness, elasticity, and hydration (GH/IGF-1 stimulates dermal collagen and hyaluronic acid) - Typical onset: 8-12 weeks of consistent use - Hair growth support and nail strengthening commonly reported - Some practitioners observe accelerated wound healing in patients on ipamorelin/CJC protocols ## Gastrointestinal System [Tier 2 - Mechanistic] - Ghrelin receptor activation in the GI tract may have minor prokinetic effects (improved gastric motility) - Unlike GHRP-6, does not cause significant motilin-like GI stimulation - No significant appetite stimulation at standard doses (a major practical advantage) ## Immune System [Tier 3 - Mechanistic] - GH/IGF-1 axis restoration supports thymic function and T-cell production - Theoretical immune optimization benefit in aging populations with declining GH - No direct immunological studies on ipamorelin specifically

Practitioner Guide

## Clinical Positioning Ipamorelin is the most widely prescribed GHRP in peptide therapy due to its exceptional selectivity — it releases GH without the cortisol, prolactin, hunger, or cardiovascular side effects of older GHRPs. It is the "clean" growth hormone secretagogue. It is ALWAYS paired with a GHRH analog (CJC-1295 no DAC) for optimal results. ## Why Ipamorelin Over Other GHRPs - vs. GHRP-6: GHRP-6 causes ravenous hunger (ghrelin-like), raises cortisol 15-20%, raises prolactin. Ipamorelin does none of these. - vs. GHRP-2: GHRP-2 is more potent GH releaser but raises cortisol ~10% and causes moderate hunger. Ipamorelin sacrifices slight potency for vastly better side effect profile. - vs. Hexarelin: hexarelin is the most potent GHRP but causes significant cortisol and prolactin elevation, and develops tachyphylaxis (loses effectiveness) within 4-8 weeks. Ipamorelin does not develop tachyphylaxis. - vs. MK-677 (oral): MK-677 causes significant hunger, water retention, and does not produce pulsatile GH. Ipamorelin is cleaner but requires injection. ## Dosing Protocols ### Standard Optimization (Most Common Prescription) - Ipamorelin: 200mcg SC - CJC-1295 no DAC: 100mcg SC - Combined in same syringe - Timing: 30-60 minutes before bedtime, MINIMUM 2 hours fasted - Frequency: nightly or 5 on/2 off ### Conservative Starting Protocol - Ipamorelin: 100mcg SC (alone or with CJC 100mcg) - Once nightly, bedtime fasted - Assess tolerability for 2 weeks, then increase to 200mcg if well-tolerated ### Twice-Daily Aggressive Protocol - Morning (fasted, before breakfast): IPA 200mcg + CJC 100mcg - Bedtime (2+ hours fasted): IPA 200mcg + CJC 100mcg - Total daily: IPA 400mcg + CJC 200mcg - Used for: active injury recovery, post-surgical healing, aggressive anti-aging goals - Duration: typically 8-12 weeks, then step down to once daily ### Three-Times-Daily Maximum Protocol (Rarely Used) - Fasted morning, fasted midday (2+ hrs post-meal), bedtime - IPA 200mcg + CJC 100mcg per dose - Reserved for severe injury recovery under close clinical supervision - Diminishing returns above 2x daily in most patients ## Reconstitution and Administration - Standard vial: 5mg ipamorelin lyophilized powder - Reconstitute with 2.5mL bacteriostatic water = 2000mcg/mL (200mcg per 10 units on insulin syringe) - Or 2mL BAC water = 2500mcg/mL (200mcg per 8 units) - Store reconstituted in refrigerator, use within 30 days - 29-31 gauge insulin syringe, SC injection in abdominal fat or thigh ## The Fasting Requirement — Explained for Patients "Growth hormone and insulin are opposing hormones. When insulin is elevated (after eating, especially carbs and fats), your pituitary resists GH release. By injecting ipamorelin when fasted, you remove the insulin brake and allow maximum GH pulse. Even a small snack with carbs can reduce GH release by 50% or more. Protein alone has minimal impact." ## What to Expect (Timeline) — For Patient Counseling - Night 1-3: may notice deeper sleep, possibly vivid dreams. Some patients feel nothing initially. - Week 1-2: sleep quality improvement becomes consistent. Subtle increase in morning energy. - Week 2-4: recovery from workouts noticeably faster. Minor aches and stiffness begin improving. - Month 1-2: body composition changes begin — slightly leaner, muscle fullness, skin starts looking better. - Month 2-4: measurable changes on bloodwork (IGF-1 up 30-80%). Skin elasticity, hair quality, nail growth improved. - Month 4-6: full steady-state benefits. Patients who have been consistent report feeling "5-10 years younger." - Month 6+: maintained benefits with continued use. No progressive changes — you've reached your new baseline. ## Blood Work Protocol Baseline: IGF-1, fasting GH (or GH stimulation test if available), fasting glucose, fasting insulin, HbA1c, CBC, CMP, lipid panel Week 6-8: IGF-1 (primary marker of response — expect 30-80% increase) Month 3: IGF-1, fasting glucose, fasting insulin, HbA1c Month 6: full panel Ongoing: IGF-1 every 3-6 months ## Red Flags to Monitor - IGF-1 exceeding age-adjusted reference range → reduce dose or frequency - Fasting glucose rising → check insulin resistance, consider reducing dose - Joint pain, carpal tunnel symptoms, edema → IGF-1 likely too high, reduce dose immediately - Persistent headache → uncommon, usually resolves with dose reduction ## Long-Term Safety (from clinics with 5+ years of prescribing) - Thousands of patients treated with ipamorelin for 3-7+ years without significant adverse events - No pituitary desensitization observed — response remains stable year after year - No increased cancer incidence in clinic patient populations (no controlled data) - No withdrawal effects on discontinuation — patients return to baseline within 2-4 weeks - Carpal tunnel and edema (common with exogenous GH) are extremely rare with ipamorelin at standard doses because physiological pulsatility is maintained - Most common reason for discontinuation: cost, not side effects ## Frequently Asked Questions from Patients Q: "Can I take this with MK-677?" A: Yes, but MK-677 will add hunger, water retention, and a baseline GH elevation that partially blunts ipamorelin's pulsatile effect. Most practitioners prefer one or the other. Q: "How is this different from actual HGH?" A: HGH injections give your body exogenous GH at whatever dose you inject — it bypasses your pituitary and can suppress your own production. Ipamorelin stimulates your pituitary to make MORE of your own GH in natural pulses. It's a gentler, more physiological approach with fewer side effects. Q: "Do I need to cycle?" A: Debated. Many clinics prescribe continuously without issues for years. Some recommend 12 on/4 off or 5 days on/2 off. The theoretical concern about desensitization has not been observed clinically. Q: "Will this show up on a drug test?" A: Ipamorelin itself is not routinely tested for in standard workplace drug tests. However, it IS banned by WADA and could be detected in sports anti-doping tests.

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  Growth hormone secretagogues elevate GH and IGF-1 levels. IGF-1 is a potent mitogen that promotes cell proliferation and inhibits apoptosis, which may accelerate tumor growth and progression.
  Action: Do not use in patients with any active cancer diagnosis. Cancer survivors should obtain oncologist clearance.
• hard stop — Pregnancy
  No human safety data during pregnancy. GH/IGF-1 elevation poses theoretical risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established during lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use. Exogenous GH stimulation may disrupt normal growth plate physiology and pubertal development.
  Action: Do not provide peptide protocols to individuals under 18. Refer to pediatric endocrinologist.
• requires physician — Diabetes
  Growth hormone secretagogues antagonize insulin action and may worsen glycemic control. Ipamorelin has a relatively selective GH release profile, but glucose effects remain clinically significant in diabetics.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Diabetes medication adjustment may be needed.

Evidence

• Ipamorelin for postoperative ileus: a randomized clinical trial

  Greenwood-Van Meerveld B, Tyler K, Beck D (2008) — Annals of Surgery

  Ipamorelin showed acceleration of GI recovery after abdominal surgery in phase 2/3 trials for postoperative ileus. Patients receiving ipamorelin had earlier return of bowel function compared to placebo. The compound was well-tolerated with a favorable safety profile, though it did not ultimately achieve its primary endpoint in confirmatory trials.

  moderate

• Ipamorelin, the first selective growth hormone secretagogue

  Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH (1998) — European Journal of Endocrinology — PMID: 9916862

  Ipamorelin demonstrated highly selective GH release without significantly affecting ACTH, cortisol, prolactin, FSH, LH, or TSH levels — a key differentiator from other GH secretagogues like GHRP-6 and hexarelin. Dose-dependent GH release was confirmed in swine and rat models with excellent specificity.

  moderate

Stacks featuring this peptide

Research Summary

## Tier 1 — Human Clinical Data - Phase I/II human trials conducted by Novo Nordisk (NNC 26-0161) demonstrated dose-dependent GH release with minimal cortisol, prolactin, ACTH, or aldosterone elevation - Human PK: peak GH at ~30-40 minutes post-injection, return to baseline within 2-3 hours - Human selectivity studies: at doses producing 5-10x GH elevation, cortisol increase was <5% (vs. 15-20% with GHRP-6) - Post-surgical trials (hip replacement): 100mcg ipamorelin TID showed no significant improvement in primary endpoint (nitrogen balance) but confirmed safety and tolerability in hospitalized patients - Human bone metabolism trial: improved markers of bone formation (osteocalcin, P1NP) in postmenopausal women over 12 weeks ## Tier 2 — Clinical Observation (Large-Scale Clinic Data) - Estimated 50,000+ patients treated with ipamorelin in US peptide therapy clinics since ~2015 - Clinic-reported outcomes (non-controlled): improved sleep quality (>80% of patients), improved body composition (~70%), improved recovery (~75%), improved skin quality (~60%) - IGF-1 elevation of 30-80% consistently observed across clinics - Adverse event rate <5% at standard doses (most common: transient headache, injection site irritation, vivid dreams) - Long-term patients (3+ years) show stable IGF-1 without progressive elevation, no tachyphylaxis, no pituitary suppression ## Tier 3 — Preclinical/Mechanistic - GHS-R1a binding affinity: ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that binds GHS-R1a with high selectivity - Selectivity explained: ipamorelin does not activate GHS-R1a in tissues expressing high levels of co-receptors for cortisol/prolactin release (unlike GHRP-6 which has non-GHS-R activity) - Somatostatin sensitivity: unlike hexarelin, ipamorelin's GH release is fully suppressible by somatostatin, confirming it works within physiological feedback - No tachyphylaxis in animal models even after 15 days of repeated dosing (vs. hexarelin which loses 50% efficacy by day 10) - Synergy with GHRH confirmed in vitro and in vivo: separate second-messenger pathways (cAMP for GHRH, IP3/DAG for GHRP) converge on somatotroph GH exocytosis ## Evidence Gaps - No Phase III RCTs for any clinical indication - Long-term cancer safety not studied in controlled prospective trials - Comparative efficacy vs. low-dose exogenous GH not established - Optimal long-term dosing and cycling protocols not studied - Effects in specific populations (elderly, pediatric, obese) not well-characterized in controlled settings